These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30518564)

  • 21. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two TPX2-dependent switches control the activity of Aurora A.
    Xu X; Wang X; Xiao Z; Li Y; Wang Y
    PLoS One; 2011 Feb; 6(2):e16757. PubMed ID: 21347367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.
    Burgess SG; Oleksy A; Cavazza T; Richards MW; Vernos I; Matthews D; Bayliss R
    Open Biol; 2016 Jul; 6(7):. PubMed ID: 27411893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.
    de Souza VB; Kawano DF
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129448. PubMed ID: 31676293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.
    Bayliss R; Sardon T; Vernos I; Conti E
    Mol Cell; 2003 Oct; 12(4):851-62. PubMed ID: 14580337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
    Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
    Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.
    Yan M; Wang H; Wang Q; Zhang Z; Zhang C
    Phys Chem Chem Phys; 2016 Apr; 18(15):10367-74. PubMed ID: 27029952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The multifaceted allosteric regulation of Aurora kinase A.
    Levinson NM
    Biochem J; 2018 Jun; 475(12):2025-2042. PubMed ID: 29946042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein.
    Satinover DL; Leach CA; Stukenberg PT; Brautigan DL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8625-30. PubMed ID: 15173575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.
    Janeček M; Rossmann M; Sharma P; Emery A; Huggins DJ; Stockwell SR; Stokes JE; Tan YS; Almeida EG; Hardwick B; Narvaez AJ; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR
    Sci Rep; 2016 Jun; 6():28528. PubMed ID: 27339427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic.
    Dodson CA; Bayliss R
    J Biol Chem; 2012 Jan; 287(2):1150-7. PubMed ID: 22094468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis of specific binding between Aurora A and TPX2 by molecular dynamics simulations.
    Cheng Y; Zhang F; Chen Q; Gao J; Cui W; Ji M; Tung CH
    J Chem Inf Model; 2011 Oct; 51(10):2626-35. PubMed ID: 21919471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel mechanism for activation of the protein kinase Aurora A.
    Eyers PA; Erikson E; Chen LG; Maller JL
    Curr Biol; 2003 Apr; 13(8):691-7. PubMed ID: 12699628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
    Ding X; Liu X; Song X; Yao J
    Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.
    Bibby RA; Tang C; Faisal A; Drosopoulos K; Lubbe S; Houlston R; Bayliss R; Linardopoulos S
    J Biol Chem; 2009 Nov; 284(48):33177-84. PubMed ID: 19801554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A FRET biosensor reveals spatiotemporal activation and functions of aurora kinase A in living cells.
    Bertolin G; Sizaire F; Herbomel G; Reboutier D; Prigent C; Tramier M
    Nat Commun; 2016 Sep; 7():12674. PubMed ID: 27624869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.